drugset / Trial / NCT04042623
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label Phase 2a clinical study designed to evaluate the safety and efficacy of AVB-S6-500 in patients with IgA Nephropathy (IgAN). Approximately 24 patients will be enrolled. Several dose levels of AVB-S6-500 may be evaluated.
Timeline
- Start
- 2019-11-27
- Primary completion
- 2020-08-01
- Completion
- 2020-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Batiraxcept | Protein / enzyme biologic | — | Intravenous |